Reconsidering Adjuvant Immunotherapy for Tuberculosis
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Shortened regimens for treatment of pulmonary tuberculosis (TB) are urgently needed to facilitate its global eradication. Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas. METHODS: The medical literature was reviewed to identify clinical trials of adjuvant TB immunotherapy, as well as other studies of the relationship between immune status and TB relapse or reactivation. RESULTS: Four studies of therapeutic interferon indicated its inability to effectively augment the mycobactericidal capacity of lung macrophages. One randomized, placebo-controlled trial of therapeutic interleukin-2 found that it delayed the microbiologic response to treatment, whereas 2 controlled trials of anti-tumor necrosis factor (TNF) therapies (high-dose prednisolone and etanercept [a soluble TNF receptor]) found that these interventions significantly accelerated the response to treatment. Four retrospective studies were identified in which the response to TB therapy was accelerated and/or the relapse risk was reduced in persons with human immunodeficiency virus coinfection; one study reported that immune reconstitution syndrome due to use of antiretroviral therapy was associated with increased risk of relapse. Several studies indicated that granulomas may be efficiently targeted and disrupted by the anti-TNF antibody infliximab, apparently because of its ability to bind to cell-surface TNF and to induce apoptosis in TNF-expressing cells. CONCLUSIONS: These findings support the hypothesis that the granulomatous host response to TB may paradoxically protect sequestered mycobacteria from administered anti-TB therapy and that treatment may be improved by therapeutic disruption of granulomas. Clinical trials to test this hypothesis are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149 · cited 1×
“ing domains, as a soluble homotrimer [26, 27].”
Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schrelber, R., Mak, T. W., & Bloom, B. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90001-2 · Cited by 1,677 · cited 1×
“As a result, animals deficient in TNF are highly susceptible to granulomatous infections [41].”
BackgroundMcKinney, J. D., zu Bentrup, K. H., Muñoz-Elías, E. J., Miczak, A., Chen, B., Chan, W.-T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,360 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundKindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254 · cited 1×
“tuberculosis infection and inhibits the orderly formation of granulomas [37, 38].”
BackgroundChan, J., Xing, Y., Magliozzo, R. S., & Bloom, B. R. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.4.1111 · Cited by 1,062 · cited 1×
“production of reactive nitrogen intermediates, such as nitric oxide [16, 17].”
BackgroundGranulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Self-citationInhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., & Schoolnik, G. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030205 · Cited by 966 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundEtanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910 · cited 1×
“Crohn disease, sarcoidosis, or Wegener granulomatosis [68-71].”
Interferon-γ –Receptor Deficiency in an Infant with Fatal Bacille Calmette–Guérin Infection
Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J.-F., Newport, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352604 · Cited by 895
Research works printed but not linked: 10
- O’Brien RJ, 2001, Global Alliance for TB Drug Development. Tuberculosis, 81, 1
- Giosue S, 2000, Eur Cytokine Netw, 11, 99
- InterMune investor relations press release: InterMune enrolls first patient in phase III trial in multidrug-resistant tuberculosis. 2000. Available at: http://www.hopkins-tb.org/news/7-31-2000.shtml. Accessed 18 May 2005.
- de Oliveira MM, 2004, Jornal Brasileiro Pneumologia, 30, 461
- East African-British Medical Research Councils, 1974, Lancet, 2, 237
- Bilaceroglu S, 1999, Int J Tuberc Lung Dis, 3, 47
- Dhillon J, 1989, Br J Exp Pathol, 70, 103
- Batten JC, 1957, Br J Exp Pathol, 38, 424
- Flynn JL, 2004, Tuberculosis. Philadelphia: Lippincott Williams & Wilkins, 237
- Joloba ML, 2000, Int J Tuberc Lung Dis, 4, 528
Cited by
Roca, F. J., & Ramakrishnan, L. (2013) · Cell · doi:10.1016/j.cell.2013.03.022 · Cited by 592
“Second, that these susceptibility pathways could be TNF-mediated is supported by a clinical trial from Uganda showing that pulmonary TB patients had increased clearance of sputum bacteria when treated with TNF blocking agents (Wallis, 2005).”
ResultHost Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections
Tobin, D. M., Roca, F. J., Oh, S. F., McFarland, R., Vickery, T. W., Ray, J. P., Ko, D. C., Zou, Y., Bang, N. D., Chau, T. T. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.023 · Cited by 580
“In addition, anti-TNF therapies have been reported to accelerate the bacteriological response in pulmonary TB patients (Wallis, 2005).”
BackgroundCurrent diagnosis and management of peripheral tuberculous lymphadenitis.
Fontanilla, J.-M., Barnes, A., & von Reyn, C. F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir454 · Cited by 299
“Adjuvant immunotherapy with anti–tumor necrosis factor agents has been studied in small numbers of patients for routine treatment of all forms of tuberculosis, but available data are insufficient to make a recommendation [51].”
BackgroundTumour necrosis factor antagonists: structure, function, and tuberculosis risks
Wallis, R. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70227-5 · Cited by 275
Self-citationThe risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement
Bumbacea, D., Arend, S. M., Eyuboglu, F., Fishman, J. A., Goletti, D., Ison, M. G., Jones, C. E., Kampmann, B., Kotton, C. N., Lange, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00000712 · Cited by 264
“Potential improvement could be obtained by new drug combinations including novel drugs such as the diarylquinoline TMC207 [167], or combinations with immunopotentiators [168, 169].”
BackgroundStanley, S. A., Barczak, A. K., Silvis, M. R., Luo, S. S., Sogi, K., Vokes, M., Bray, M.-A., Carpenter, A. E., Moore, C. B., Siddiqi, N., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003946 · Cited by 251
“tuberculosis to transition into a state of active replication in which it is sensitive to antibiotics [57].”
BackgroundLin, P. L., Myers, A., Smith, L., Bigbee, C., Bigbee, M., Fuhrman, C., Grieser, H., Chiosea, I., Voitenek, N. N., Capuano, S. V., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27271 · Cited by 244
“This disparity in findings may be due to the inherent nature of murine granulomas, which are loosely organized aggregates of inflammatory cells, compared to the distinct architecture of tightly localized inflammatory cells seen in zebrafish and primates [1,2].”
Blackmore, T. K., Manning, L., Taylor, W. J., & Wallis, R. S. (2008) · Clinical Infectious Diseases · doi:10.1086/592695 · Cited by 179
Self-citationHost-Directed Therapeutics for Tuberculosis: Can We Harness the Host?
Hawn, T. R., Matheson, A. I., Maley, S. N., & Vandal, O. H. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00032-13 · Cited by 173
“Etanercept (141, 142) 16 (PTB) Single-arm trial of etanercept (n 16)”
Adalimumab Treatment of Life‐Threatening Tuberculosis
Wallis, R. S., van Vuuren, C., & Potgieter, S. (2009) · Clinical Infectious Diseases · doi:10.1086/598504 · Cited by 129
“This may be attributable to enhanced penetration of TB drugs into granulomas or enhanced drug bactericidal activity against metabolically active bacilli [22, 23].”
BackgroundSelf-citationStäger, S., Maroof, A., Zubairi, S., Sanos, S. L., Köpf, M., & Kaye, P. M. (2006) · European Journal of Immunology · doi:10.1002/eji.200635937 · Cited by 121
“Although DC function in infectious disease models has been most commonly studied at the onset of infection, DC are also likely to play an important role in regulating immunity at later stages of the disease process, as evident from the success of DC-based immunotherapy in experimental and clinical studies [12-17].”
BackgroundInfectious Complications Associated with Monoclonal Antibodies and Related Small Molecules
Salvaña, E. M. T., & Salata, R. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-08 · Cited by 116
“Finally, the discontinuation of immunosuppressive therapy may result in a paradoxical worsening of the infection as the immune system recovers and reacts to persistent but heretofore unrecognized antigens—a phenomenon termed immune reconstitution inflammatory syndrome in the human immunodeficiency virus (HIV)/AIDS lit…”
BackgroundPenitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view
Paige, C., & Bishai, W. R. (2010) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01424.x · Cited by 96
“Patients who received adjunctive TNF-a inhibitor therapy with etanercept for the first 4 weeks of treatment demonstrated an acceleration of sputum conversion to culture negativity (Wallis et al., 2004; Wallis, 2005).”
BackgroundInfectious complications of tumor necrosis factor blockade
Wallis, R. S. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832dda55 · Cited by 90
Self-citationSubbian, S., Tsenova, L., O’Brien, P. E., Yang, G., Koo, M.-S., Peixoto, B., Fallows, D. A., Zeldis, J. B., Muller, G. W., & Kaplan, G. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.039 · Cited by 89
“Consequently, there has been some interest in identifying immune modulators that reduce TNF- production as a means to limit inflammation and improve treatment outcome in TB patients.(14,15) For example, thalidomide has been shown to reduce TNF- production in patients with pulmonary TB and to improve treatment outcome.”
BackgroundParadoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis
Cho, O.-H., Park, K.-H., Kim, T., Song, E. H., Jang, E.-Y., Lee, E. J., Chong, Y. P., Choi, S.-H., Lee, S.-O., Woo, J. H., et al. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.05.006 · Cited by 87
“However, recent studies suggest that immunotherapy with steroids or an anti-TNF-a inhibitor may help to resolve PR by inhibiting granuloma formation interfering with penetration of antiTB drugs.(15,16) Further studies are needed to evaluate the adjunctive role of immunotherapy in patients at high risk for PR.”
BackgroundKoo, M.-S., Manca, C., Yang, G., O'Brien, P., Sung, N., Tsenova, L., Subbian, S., Fallows, D., Muller, G., Ehrt, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017091 · Cited by 76
“Some evidence to support this hypothesis is available from clinical trials using immune modulators as adjunctive therapy in treatment of pulmonary TB [15,16].”
Skerry, C. M., Harper, J. S., Klunk, M. H., Bishai, W. R., & Jain, S. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039680 · Cited by 74
“This hypothesis is supported by case reports and small series that demonstrate that adjunctive use of TNF-a inhibitors with TB treatments is beneficial [11,12,13,14].”
ResultArend, S. M., Leyten, E. M. S., Franken, W. P. J., Huisman, E., & van Dissel, J. T. (2007) · Clinical Infectious Diseases · doi:10.1086/522993 · Cited by 75
Pulmonary tuberculosis with acute respiratory failure
Kim, Y. J., Pack, K. M., Jeong, E., Na, J. O., Oh, Y.-M., Lee, S. D., Kim, W. S., Kim, D. S., Kim, W. D., & Shim, T. S. (2008) · European Respiratory Journal · doi:10.1183/09031936.00070907 · Cited by 73
Maïga, M., Agarwal, N., Ammerman, N. C., Gupta, R., Guo, H., Maiga, M. C., Lun, S., & Bishai, W. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030749 · Cited by 70
“Immunomodulatory agents that inhibit TNF-a have been associated with both positive and adverse outcomes in TB patients [17,20,21].”
Gräb, J., Suárez, I., van Gumpel, E., Winter, S., Schreiber, F., Esser, A., Hölscher, C., Fritsch, M., Herb, M., Schramm, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08405-9 · Cited by 71
Advances in Immunotherapy for Tuberculosis Treatment
Churchyard, G., Kaplan, G., Fallows, D. A., Wallis, R. S., Onyebujoh, P., & Rook, G. A. W. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.08.009 · Cited by 63
Self-citationBactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis
Saliu, O. Y., Crismale, C., Schwander, S., & Wallis, R. S. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm291 · Cited by 63
“– 12 It is thought that sterilizing activity reflects effects on semi-dormant bacillary subpopulations sequestered in low-oxygen microenvironments such as granulomas.(13,14) Its in vitro and pharmacokinetic correlates remain to be defined.”
BackgroundSelf-citationL-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis
Ralph, A. P., Kelly, P. M., & Anstey, N. M. (2008) · Trends in Microbiology · doi:10.1016/j.tim.2008.04.003 · Cited by 73
Diagnosis and treatment of lung infection with nontuberculous mycobacteria
Arend, S. M., van Soolingen, D., & Ottenhoff, T. H. M. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283292679 · Cited by 54
“Adjunctive cytokine treatment of NTM infections with IFN-g or other cytokines may have a place in patients with an identified inherited cellular immune deficiency[76‐79].Inpatientswithtuberculosis,theuse of cytokines or immunomodulating drugs such as thalidomide or antagonists of TNF-ahad a variable effect on outcome…”
BackgroundDeng, W., Min, Y., Ma, H., Hu, L. A., Chen, G., Wang, Y., Deng, J., Li, C., Tong, J., & Wang, D. X. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-121 · Cited by 53
“The efficacy of systemic corticosteroids is well-documented for several extrapulmonary complications of tuberculosis such as tuberculous meningitis and tuberculous pericarditis [24-28], as well as ARDS[29-32].”
BackgroundRand, L., Green, J. A., Saraiva, L., Friedland, J. S., & Elkington, P. T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801935 · Cited by 51
“Immunomodulation has been proposed as a novel therapeutic approach to tuberculosis (44), and our data demonstrate that part of the mechanism of action of PAS is to down-regulate excessive host inflammatory immune responses by inhibiting PG-driven MMP-1 secretion.”
BackgroundUrinary production in the healthy horse and in horses deprived of feed and water
Rumbaugh, G. E., Carlson, G. P., & Harrold, D. R. (1982) · American Journal of Veterinary Research · doi:10.2460/ajvr.1982.43.04.735 · Cited by 51
Mycobacterial disease in patients with rheumatic disease
van Ingen, J., Boeree, M. J., Dekhuijzen, P. R., & van Soolingen, D. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0949 · Cited by 51
“Furthermore, the disruption of granuloma formation by anti-TNF agents could increase exposure of the bacteria to antimycobacterial drugs, resulting in improved outcomes for the infection”
BackgroundGM-CSF targeted immunomodulation affects host response to M. tuberculosis infection
Benmerzoug, S., Marinho, F. V., Rose, S., Mackowiak, C., Gosset, D., Sedda, D., Poisson, E., Uyttenhove, C., Snick, J. V., Jacobs, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26984-3 · Cited by 51
Marx, F. M., Yaesoubi, R., Menzies, N. A., Salomon, J. A., Bilinski, A., Beyers, N., & Cohen, T. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30022-6 · Cited by 47
van Ingen, J., Boeree, M. J., Janssen, M., Ullmann, E. F., de Lange, W., de Haas, P., Dekhuijzen, R. P. N., & van Soolingen, D. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0538 · Cited by 44
“Firstly, the disruption of granuloma achieved by anti-TNF agents could increase the exposure of mycobacteria to antimycobacterial drugs, thereby resulting in improved treatment outcome for the infection”
BackgroundBiologics and Infections: Lessons from Tumor Necrosis Factor Blocking Agents
Wallis, R. S. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2011.08.002 · Cited by 41
Self-citationPrevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy
Buccheri, S., Reljić, R., Caccamo, N., Meraviglia, S., Iványi, J., Salerno, A., & Dieli, F. (2008) · Tuberculosis · doi:10.1016/j.tube.2008.09.001 · Cited by 39
Infliximab therapy in two cases of severe neurotuberculosis paradoxical reaction
Molton, J. S., Huggan, P. J., & Archuleta, S. (2015) · The Medical Journal of Australia · doi:10.5694/mja14.00716 · Cited by 35
Yang, J. Y., Han, M., Koh, Y., Kim, W., Song, J.-W., Oh, Y., Lee, S., Lee, S. W., Lee, J., Lim, C., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw616 · Cited by 34
“Moreover, they can promote the penetration of antituberculosis drugs into granulomas by disrupting granuloma formation [27].”
BackgroundPark, S.-K., Cho, S., Lee, I.-H., Jeon, D.-S., Hong, S.-H., Smego, R. A., & Cho, S.-N. (2007) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2006.12.004 · Cited by 34
Rivoisy, C., Amrouche, L., Carcelain, G., Séréni, D., & Bourgarit, A. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2011.01.003 · Cited by 32
A multi-scale approach to designing therapeutics for tuberculosis
Linderman, J. J., Cilfone, N. A., Pienaar, E., Gong, C., & Kirschner, D. E. (2015) · Integrative Biology · doi:10.1039/c4ib00295d · Cited by 35
Tuberculosis into the 2010s: Is the Glass Half Full?
Ralph, A. P., Anstey, N. M., & Kelly, P. (2009) · Clinical Infectious Diseases · doi:10.1086/600889 · Cited by 29
“the basis of the hypothesis that amelioration of cytokine-mediated pathology might be advantageous in some forms of TB, other combined immunosuppressive-therapeutic strategies have also been advocated [67, 68].”
BackgroundLee, H., Lee, Y., Lee, S., Choi, S., Kim, Y. S., Woo, J. H., & Kim, S. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-011-0334-y · Cited by 26
“tuberculosis from the administered anti-TB therapy, suggesting that treatment might be improved by therapeutic disruption of the granulomas [2].”
InfluentialTuberculose grave com necessidade de internação em UTI
Silva, D. R., Gazzana, M. B., & Dalcin, P. D. T. R. (2012) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132012000300015 · Cited by 26
Tanaka, T., Sekine, A., Tsunoda, Y., Takoi, H., Lin, S.-Y., Yatagai, Y., Hayasihara, K., & Saito, T. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.2828 · Cited by 25
Novel Adjunctive Therapies for the Treatment of Tuberculosis
Ordoñez, A. A., Maïga, M., Gupta, S., Weinstein, E. A., Bishai, W. R., & Jain, S. K. (2014) · Current Molecular Medicine · doi:10.2174/1566524013666131118112431 · Cited by 27
“These animal data are also supported by case reports and small clinical series that demonstrate that adjunctive use of TNF-α inhibitors with TB treatment are beneficial [77, 79-81].”
ResultPotential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis
Man, D. K.-W., Chow, M. Y. T., Casettari, L., Juarrero, M. G., & Lam, J. K. W. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.013 · Cited by 31
Eisen, D. P., McBryde, E. S., & Walduck, A. K. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit476 · Cited by 24
Immunity to TB and Targets for Immunotherapy
Juarrero, M. G. (2012) · Immunotherapy · doi:10.2217/imt.11.168 · Cited by 23
Immune Reconstitution Inflammatory Syndrome Associated with Biologic Therapy
Gupta, M., Jafri, K., Sharim, R. R., Silverman, S., Sindher, S., Shahane, A., & Kwan, M. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0499-4 · Cited by 21
Nikolaeva, L. G., Maystat, T. V., Pylypchuk, V. S., Volyanskii, Y. L., Frolov, V. M., & Kutsyna, G. A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.10.009 · Cited by 21
“This clinical study revealed potential antagonism between TB drugs and immunotherapy and suggested that exogenous supplementation with cytokines will not necessarily fulfill expectations based on mechanistic studies [14].”
BackgroundResultInfluentialChiu, Y., Tang, C., Hung, S., Yang, Y.-W., Fang, C.-H., & Lin, H.-Y. (2016) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2016.1202318 · Cited by 21
“One distinction is the efficacy of the monoclonal antibodies against chronic granulomatous inflammatory diseases such as Crohn’s disease, which is not observed with etanercept; this is at least partly attributed to the ability of the monoclonal antibodies to induce apoptosis in activated T cells and downregulate the p…”
BackgroundOrdoñez, A. A., Pokkali, S., Kim, S.-H., Carr, B., Klunk, M. H., Tong, L., Saini, V., Chang, Y. S., McKevitt, M. T., Smith, V., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197474 · Cited by 21
Doherty, T. M. (2012) · Immunotherapy · doi:10.2217/imt.12.52 · Cited by 20
Cytokine therapy of tuberculosis at the crossroads
Reljić, R., Paul, M. J., & Arias, M. A. (2009) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.3.1.53 · Cited by 20
Schön, T., Lerm, M., & Stendahl, O. I. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12031 · Cited by 20
Is it safe to readminister tumor necrosis factor α antagonists following tuberculosis flare?
Aslanidis, S., Pyrpasopoulou, A., Δούμα, Σ., & Petidis, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23210 · Cited by 19
Miles, D. J. C., van der Sande, M. A. B., Crozier, S., Ojuola, O. O., Palmero, M. S., Sanneh, M., Touray, E. S., Rowland‐Jones, S., Whittle, H. C., Ota, M. O. C., et al. (2008) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00037-08 · Cited by 23
“of IFN- in tuberculosis patients has not been successful (47),”
BackgroundLwin, N., Boyle, M., & Davis, J. S. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy027 · Cited by 18
“In our patient, interrupting very active inflammation and granuloma formation by TNF blockade may have discouraged the exaggerated immune response, which is important to the development of IRIS, while enhancing bacteria killing by maximizing drug penetration into the granulomas [13].”
BackgroundCorticosteroid Effects on Sputum Culture in Pulmonary Tuberculosis: A Meta-Regression Analysis
Wallis, R. S. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu020 · Cited by 20
“anti-inflammatory treatment, which could potentially facilitate drug penetration into lung lesions and thereby increase effectiveness [3].”
BackgroundSelf-citationTreatment of tuberculosis in children
Cruz, A. T., & Starke, J. R. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.6.939 · Cited by 18
Mori, S., & Sugimoto, M. (2011) · Clinical Rheumatology · doi:10.1007/s10067-011-1902-3 · Cited by 17
“based on the hypothesis that granulomatous host response may paradoxically protect mycobacteria from anti-mycobacterial drugs [39].”
BackgroundCytokines as Immunomodulators in Tuberculosis Therapy
Rivero-Lezcano, O. M. (2008) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489108786242332 · Cited by 20
“However, few studies have been published investigating its clinical use [61].”
BackgroundIn silico models of M. tuberculosis infection provide a route to new therapies
Linderman, J. J., & Kirschner, D. E. (2014) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2014.02.006 · Cited by 18
“Several strategies have been tried in murine models (e.g. addition of exogenous cytokines IFN-γ , GM-CSF, TNF, IL-12; reviewed in [36,37]) and a few in humans (addition of exogenous cytokines IL-2, GM-CSF, TNF, IFN-γ ) [36,38], but results are inconclusive.”
ResultSzerszen, A., Gupta, S., Seminara, D., Jarrett, M. P., & Goldstein, M. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181bc9407 · Cited by 16
“Others suggest the possibility of continuation of anti-TNF therapy throughout the TB treatment and others still who recommend instituting a corticosteroid, a notion examined in our case report.(3)”
BackgroundZellweger, J.-P. (2007) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.1.1.85 · Cited by 15
Qiao, M., Li, S., Yuan, J., Ren, W., Shang, Y., Wang, W., Liu, R., Zhang, F., Li, Q., Wu, X. Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923492 · Cited by 14
“Conventionally, much attention has been focused on identifying the agents that could boost proinflammatory responses aiming to kill and sequester the pathogens invading host cells (16, 38).”
BackgroundPulmonary Infectious Complications of Tumor Necrosis Factor Blockade
Wallis, R. S., & Schluger, N. W. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.04.010 · Cited by 14
Self-citationSchwartz, Y. S., Белогородцев, С. Н., Николаевич, Ф. П., Чередниченко, А. Г., Pustylnikov, S., & Va, K. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.09.005 · Cited by 14
“vaccae have 11 shown limited efficiency in TB treatment [4-7].”
BackgroundDoes sphingosine 1-phosphate play a protective role in the course of pulmonary tuberculosis?
Garg, S. K., Santucci, M. B., Panitti, M., Pucillo, L. P., Bocchino, M., Okajima, F., Bisen, P. S., Saltini, C., & Fraziano, M. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.09.002 · Cited by 14
Recent Advances in Nanotechnology-Based Strategies for Bone Tuberculosis Management
Luo, Y., Chen, H., Chen, H., Xiu, P., Zeng, J., Song, Y., & Li, T. (2024) · Pharmaceuticals · doi:10.3390/ph17020170 · Cited by 14
“…to bone The granulomatous response, while a defense mechanism, can inadvertently contribute to bone damage through chronic in fl ammation and the disruption of normal bone remodeling processes [46]. damage through chronic inflammation and the disruption of normal bone remodeling processes [46].”
BackgroundImmunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches
Achkar, J. M., Casadevall, A., & Glatman‐Freedman, A. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.3.461 · Cited by 13
Ma, J., Jung, B., Yi, N., & Samten, B. (2016) · Scandinavian Journal of Immunology · doi:10.1111/sji.12447 · Cited by 14
Review of the Effectiveness of Various Adjuvant Therapies in Treating Mycobacterium tuberculosis
Amin, A., Vartanian, A., Yegiazaryan, A., Al-Kassir, A. L., & Venketaraman, V. (2021) · Infectious Disease Reports · doi:10.3390/idr13030074 · Cited by 16
A Systems Biology Approach for Understanding Granuloma Formation and Function in Tuberculosis
Fallahi‐Sichani, M., Marino, S., Flynn, J. L., Linderman, J. J., & Kirschner, D. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4966-9_7 · Cited by 11
Nikolaeva, L. G., Maystat, T. V., Масюк, Л. А., Pylypchuk, V. S., Volyanskii, Y. L., & Kutsyna, G. A. (2009) · PubMed Central · Cited by 10
Surrogate markers to assess new therapies for drug-resistant tuberculosis
Wallis, R. S. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.2.163 · Cited by 11
“29 Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18(2), 257–264 (2004). • The only study to date of a targeted anti-tumor necrosis factor therapy in TB.”
BackgroundSelf-citationNeurotuberculosis: Control of Steroid-Refractory Paradoxical Inflammatory Reaction With Ruxolitinib
Xie, Y. L., Ita-Nagy, F., Chen, R. Y., Manion, M. M., Sereti, I., Pei, L., & Holland, S. M. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz422 · Cited by 10
Dual Role of Inflammation in Prognosis and Prevention of Tuberculosis
Majeed, S. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000298 · Cited by 10
“Patient clinical trials with IFN-γ have shown improved results in tuberculosis therapy, though some limitations are still there [104,105].”
Eshagh, D., Benali, K., Dossier, A., Chauveheid, M. P., Rouzaud, D., Goulenok, T. M., Papo, T., & Sacré, K. (2020) · Infection · doi:10.1007/s15010-020-01470-z · Cited by 7
Guyot, A., Bégon, E., Abramowitz, L., Landry, J., Marinho, E., Descamps, V., & Crickx, B. (2009) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2009.09.009 · Cited by 7
Effect of Low Doses of Dexamethasone on Experimental Pulmonary Tuberculosis
Lara-Espinosa, J. V., Arce-Aceves, M. F., Barrios‐Payán, J., Mata‐Espinosa, D., Lozano-Ordaz, V., Becerril‐Villanueva, E., Ponce-Regalado, M. D., & Hernández‐Pando, R. (2023) · Microorganisms · doi:10.3390/microorganisms11061554 · Cited by 6
“ethambutol for the first two months of the six-month treatment period [5].”
BackgroundEpidemiological, therapeutic and evolutionary profiles in patients with lymph node tuberculosis.
Jniene, A., Soualhi, M., Bouassel, M., Nayme, I., Zahraoui, R., & Iraqi, G. (2010) · PubMed · Cited by 9
Host-directed immunotherapy to enhance treatment of Mycobacterium tuberculosis infection
Ren, F., Yang, X., Li, X., Xing, J., Sun, M., Zhang, Y., & Song, N. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115455 · Cited by 9
Adjunctive corticosteroid therapy in patients with pulmonary tuberculosis
Lemos, C. X., Anton, C., Machado, F. D., Bernardi, R. M., Freitas, A. A., & Silva, D. R. (2022) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20220196 · Cited by 5
The Risk of Infections With Tumor Necrosis Factor-α Inhibitors
Jassal, M. S., & Bishai, W. R. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181c0696e · Cited by 5
“A combination of studies investigated the use of TNF-inhibitors versus steroid treatment with standard multidrug TB chemotherapy (ie, 4 months of isoniazid, rifampin, pyrazinamide ethambutol, followed by 2 months of isoniazid and rifampin).(24,25) Standard chemotherapy resulted in sputum conversion in approximately 60…”
BackgroundIntroduction to Tuberculosis: Integrated Studies for a Complex Disease
Rezaei, N., Hosseini, N., & Saghazadeh, A. (2023) · Integrated science · doi:10.1007/978-3-031-15955-8_1 · Cited by 4
Solid Swellings of the Anterior Triangle: Cervical Lymphadenopathy
Sakr, M. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-32118-4_3 · Cited by 4
Kawamoto, H., Takasaki, J., Ishii, S., Suzuki, M., Morino, E., Naka, G., Iikura, M., Izumi, S., Takeda, Y., & Sugiyama, H. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.04.013 · Cited by 5
“One report showed that the group undergoing high doses of steroid or etanercept treatment during the first month had a significantly better negative bacterial infection rate than the group treated with usual medical treatment [9], and another report stated that reinstitution of infliximab resulted in good control of R…”
ResultTuberculosis pneumonia as a primary cause of respiratory failure--report of two cases.
Puri, M. M., Kumar, S., Prakash, B., Lokender, K., Jaiswal, A., & Behera, D. (2010) · PubMed · Cited by 4
Wallis, R. S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3988-4.00070-6 · Cited by 4
Self-citationInterdisziplinäre Berührungspunkte zwischen Rheumatologie und Pneumologie
Hermann, J., Kovács, G., & Scheidl, S. J. (2008) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-008-0346-x · Cited by 5
Anti-tuberculosis treatment and infliximab
Wallis, R. S. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.06.010 · Cited by 4
Self-citationMycobacteria and Biological Response Modifiers: Two Sides of the Relationship
Sundareshan, V., Modi, J. M., & Khardori, N. M. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2011.07.010 · Cited by 2
Mycobacterium-Induced Reactive Arthritis in an Older Adult With Rheumatoid Arthritis
Yuasa, M., Suyama, K., Adachi, K., Amano, S., Sano, C., & Ohta, R. (2023) · Cureus · doi:10.7759/cureus.43057 · Cited by 3
“Standard therapeutic modalities for rheumatoid arthritis include conventional synthetic diseasemodifying antirheumatic drugs (csDMARDs), molecularly targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), biological disease-modifying antirheumatic drugs (bDMARDs), nonsteroidal anti-inflammatory drugs, and…”
BackgroundReversion of cerebral artery stenoses due to tuberculomas with TNF-α antibodies
Vandecasteele, S. J., Vriese, A. S. D., & Vanhooren, G. (2012) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2012.01.027 · Cited by 3
Dutt, N. C., & Gupta, A. (2014) · National Journal of Community Medicine · Cited by 2
Flores-Franco, R. A., Medina, D. O., Pacheco‐Tena, C., & Duque-Rodríguez, J. (2015) · Case Reports in Pulmonology · doi:10.1155/2015/283867 · Cited by 2
“In experimental models, the selective neutralization of TNF-α inhibits the formation of granulomas and reduces the microbicidal activity of macrophages and NK cells [16].”
BackgroundRivoisy, C., Amrouche, L., Carcelain, G., Séréni, D., & Bourgarit, A. (2011) · Revue du Rhumatisme · doi:10.1016/j.rhum.2010.11.011 · Cited by 2
Tumor necrosis factor-α inhibitors and granulomatous infectious
Deepe, G. S., & Wallis, R. S. (2006) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2006.06.006 · Cited by 2
Self-citationTen Questions to Challenge the Natural History of Tuberculosis
Cardona, P.-J. (2012) · InTech eBooks · doi:10.5772/30247 · Cited by 1
“…a kind of “glass roof” in this respect. www.intechopen.com Understanding Tuberculosis – Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity 14 One growing issue is trying to lie Mtb by favoring artificially their growth stopping for instance the inflammatory response [Wallis 2005].”
Background
Metadata
- Authors
- Wallis, R. S.
- Affiliations
- Pharmaceutical Product Development (United States) (US)
- Corresponding author
- Wallis, Robert S.
- ORCID
- Wallis, Robert S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-15
- Volume
- 41
- Issue
- 2
- Pages
- 201-208
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2133199321
- Cited by
- 121
- References
- 75
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 7 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 13
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Louisiana State University
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- pulmonary tuberculosis, adjuvant immunotherapy, tuberculosis relapse, granuloma, anti-TNF therapy, infliximab, etanercept, prednisolone, interleukin-2, interferon therapy, HIV coinfection, immune reconstitution inflammatory syndrome, antiretroviral therapy, tuberculosis treatment response
- MeSH terms
- Antitubercular Agents, Humans, Immunotherapy, Tuberculosis, Pulmonary, Drug Resistance, Multiple, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.